In a nutshell
This study aimed to evaluate the use of high-intensity focal ultrasound (HIFU) for the treatment of localized prostate cancer. This study found that HIFU is a safe treatment with good oncological results and minimal side-effects.
Some background
High-intensity focused ultrasound (HIFU) is a non-invasive technique that uses ultrasonic waves to heat tissue. It can be used to treat prostate cancer (PCa). It can remove the whole prostate gland or just a part of it.
The outcomes of this treatment for localized prostate cancer are still under investigation.
Methods & findings
This study included 107 patients who underwent HIFU. 88% had intermediate/high-risk disease. 54% of the patients had removal of half the prostate. 9% had removal of the cancer only and 40% had a removal of a quarter of the prostate. They were followed up for an average of 30 months. The average pre-surgery PSA was 7.7. PSA is a prostate-specific antigen. It is a marker in the blood used to monitor PCa.
After surgery, PSA dropped an average of 71%. 8% had a biochemical recurrence (rise of PSA levels) and 11% required additional treatment. 85.5% of patients did not require additional procedures after HIFU.
Side-effects from this treatment included 1% new use of pads and 14% new erectile dysfunction.
The bottom line
This study found that HIFU has good oncological results and minimal side-effects for the partial ablation of localized prostate cancer.
The fine print
This study had a selected group of patients from a single medical center. These results may not apply to all patients. Further studies are needed.
Published By :
Urology
Date :
Aug 23, 2019
